Medigen Biotechnology (ROCO:3176) Total Equity: NT$4,716 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3176 Medigen Biotechnology Corp ROCO:3176
58 GF Score
Price NT$35.40
GF Value NT$49.63
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Medigen Biotechnology Total Equity?

Medigen Biotechnology ROCO:3176 +2.31% 58 Total Equity is NT$4,716 Mil as of Dec. 2025. GuruFocus rates ROCO:3176 with a GF Score™ of 58/100 and a GF Value™ of NT$49.63 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Medigen Biotechnology's total equity for the quarter that ended in Dec. 2025 was NT$4,716 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Medigen Biotechnology Total Equity Historical Data

* Premium members only.

The historical data trend for Medigen Biotechnology's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology Total Equity Chart

Medigen Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,426.10 6,471.01 4,997.13 5,038.06 4,716.37

Medigen Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,038.06 5,095.48 4,974.60 4,897.39 4,716.37
ROCO:3176
58GF Score
Medigen Biotechnology Corp ROCO:3176
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Biotechnology Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Medigen Biotechnology's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=6180.925-1464.551
=4,716

Medigen Biotechnology's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=6180.925-1464.551
=4,716

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$4,716 Mil mean?
Medigen Biotechnology (ROCO:3176) has a Total Equity of NT$4,716 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's Total Equity too high?
Medigen Biotechnology's current Total Equity is NT$4,716 Mil. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Total Equity compare to VRTX and REGN?
Medigen Biotechnology's Total Equity of NT$4,716 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Medigen Biotechnology and its competitors. Medigen Biotechnology's current Total Equity is NT$4,716 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$49.63, compared to a current price of NT$35.40 — trading 28.7% below its estimated fair value. The current Total Equity is NT$4,716 Mil. Medigen Biotechnology's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Total Equity is NT$4,716 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued. The current stock price of NT$35.40 is trading 28.7% below its estimated GF Value™ of NT$49.63. GuruFocus considers Medigen Biotechnology to be Modestly Undervalued.

Key valuation signals for ROCO:3176:

  • Total Equity: NT$4,716 Mil
  • GF Value™: NT$49.63 vs. price of NT$35.40 (28.7% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score

Get the complete analysis for ROCO:3176

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.40
Price
NT$49.63
GF Value